semaglutide oral (BT-200) / Biora Therap - LARVOL DELTA

Are Weight Loss Medications Good for Your Heart? (Northwestern University) - "Sanjiv J. Shah, MD...co-authored a study showing that weekly doses of semaglutide improved health outcomes and quality of life for patients with heart failure with preserved ejection fraction (HFpEF). HFpEF affects nearly half of the 5 million patients in the U.S. diagnosed with heart failure annually. 'We know that obesity is tied to the HFpEF epidemic,' says Dr. Shah. "

Media quote

The Connection Between Diabetes and Heart Disease (YouTube) - "Sanjiv J. Shah, MD...join a thought-leader panel to share their insights on the connection between diabetes and heart disease, as well as using semaglutide medication for prevention. They discuss the outcomes of their recent clinical trial studies published in the New England Journal of Medicine, SELECT and STEP-HFpEF. These studies aimed to measure the effects of semaglutide in patients with obesity and pre-existing cardiovascular disease...Dr. Shah explain how the studies results complement each other and inform patient care."

Video

Advances Usher In Era of Personalized Treatment for Obesity (Gastroendonews) - '"The effectiveness of obesity pharmaceutical treatment has historically been 'less than exciting,' Dr. Chapman said, with previously FDA-approved medications delivering an average weight loss of less than 10% of total body weight. However, there has been a recent paradigm shift with the introduction of new pharmaceutical agents producing 'previously unimaginable results'....With semaglutide, 'patients can essentially achieve lower total body weight and maintain it for up to two years while on therapy,' Dr. Chapman said. 'This drug has set an outstanding precedent in the field of pharmacotherapy for obesity.'"

Media quote

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) - "Biora Therapeutics, Inc...presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany....'Across three studies, 96% of animals (22/23) showed semaglutide in systemic circulation at clinically relevant levels for up to ten days following administration....Among the 22 animals dosed with semaglutide, oral bioavailability averaged 20.5% ± 15.3%, compared to IV control, which exceeds both the device performance and bioavailability targets set by us and our collaborators...'"

Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus